

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2009; month=2; day=18; hr=13; min=52; sec=48; ms=19; ]

=====

Application No: 10518914

Version No: 2.0

Input Set:

Output Set:

Started: 2009-01-30 14:44:43.489

Finished: 2009-01-30 14:44:47.754

Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 265 ms

Total Warnings: 12

Total Errors: 36

No. of SeqIDs Defined: 12

Actual SeqID Count: 12

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)

**Input Set:**

**Output Set:**

**Started:** 2009-01-30 14:44:43.489  
**Finished:** 2009-01-30 14:44:47.754  
**Elapsed:** 0 hr(s) 0 min(s) 4 sec(s) 265 ms  
**Total Warnings:** 12  
**Total Errors:** 36  
**No. of SeqIDs Defined:** 12  
**Actual SeqID Count:** 12

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (6) This error has occurred more than 20 times, will not be displayed
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

SEQUENCE LISTING

<110> YAMAMOTO, KAZUMICHI  
SAITO, KAZUHIRO  
HOSHINO, TETSUO

<120> PROCESS FOR PRODUCING SUSTAINED-RELEASE COMPOSITION

<130> 074129-0516

<140> 10518914

<141> 2009-01-30

<150> PCT/JP03/07950

<151> 2003-06-24

<150> JP 2002-185352

<151> 2002-06-25

<160> 12

<170> PatentIn version 3.5

<210> 1

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> 5-oxo-Pro

<220>

<221> MOD\_RES

<222> (6)..(6)

<223> DLeu, DAla, DTrp, DSer(tBu), D2Nal or DHis(ImBzl)

<220>

<221> MOD\_RES

<222> (9)..(9)

<223> Pro or Pro-NH-C2H5

<220>

<221> MOD\_RES

<222> (10)..(10)

<223> Gly-NH2 or not present

<220>

<223> see specification as filed for detailed description of  
substitutions and preferred embodiments

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Gly

1 5 10

<210> 2

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> N-term may or may not be acetylated

<220>

<221> MOD\_RES

<222> (1) .. (1)

<223> N(4H2-furoyl)Gly or absent

<220>

<221> MOD\_RES

<222> (2) .. (2)

<223> D2Nal

<220>

<221> MOD\_RES

<222> (3) .. (3)

<223> D4ClPhe

<220>

<221> MOD\_RES

<222> (4) .. (4)

<223> D3Pal

<220>

<221> MOD\_RES

<222> (6) .. (6)

<223> NMeTyr, Tyr, Aph(Atz) or NMeAph(Atz)

<220>

<221> MOD\_RES

<222> (7) .. (7)

<223> DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur),  
DhArg(Et2), DAph(Atz) or DhCi

<220>

<221> MOD\_RES

<222> (9) .. (9)

<223> Lys(Nisp), Arg or hArg(Et2)

<220>

<221> MOD\_RES

<222> (11)..(11)

<223> DAla

<220>

<223> C-term amidated

<220>

<223> see specification as filed for detailed description of  
substitutions and preferred embodiments

<400> 2

Gly Xaa Phe Xaa Ser Xaa Xaa Leu Xaa Pro Ala

1 5 10

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> 5-oxo-Pro

<220>

<221> MOD\_RES

<222> (6)..(6)

<223> DLeu

<220>

<221> MOD\_RES

<222> (9)..(9)

<223> Pro-NH-C2H5

<400> 3

Pro His Trp Ser Tyr Leu Leu Arg Pro

1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (1)..(1)  
<223> 5-oxo-Pro

<220>  
<221> MOD\_RES  
<222> (6)..(6)  
<223> Ser(tBu)

<220>  
<221> MOD\_RES  
<222> (9)..(9)  
<223> Pro-NH-CH<sub>2</sub>-CH<sub>3</sub>

<400> 4  
Pro His Trp Ser Tyr Ser Leu Arg Pro  
1 5

<210> 5  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> 5-oxo-Pro

<220>  
<223> C-term amidated

<400> 5  
Pro His Trp Ser Tyr Trp Leu Arg Pro Gly  
1 5 10

<210> 6  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> 5-oxo-Pro

<220>

<221> MOD\_RES  
<222> (6) .. (6)  
<223> D2Nal

<220>  
<223> C-term amidated

<400> 6  
Pro His Trp Ser Tyr Xaa Leu Arg Pro Gly  
1 5 10

<210> 7  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (1) .. (1)  
<223> 5-oxo-Pro

<220>  
<221> MOD\_RES  
<222> (6) .. (6)  
<223> DHis(ImBzl)

<220>  
<221> MOD\_RES  
<222> (9) .. (9)  
<223> Pro-NH-CH<sub>2</sub>-CH<sub>3</sub>

<400> 7  
Pro His Trp Ser Tyr His Leu Arg Pro  
1 5

<210> 8  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (1) .. (1)  
<223> 5-oxo-Pro



<220>

<221> MOD\_RES

<222> (9) .. (9)

<223> Pro-NH-CH<sub>2</sub>-CH<sub>2</sub>-NH<sub>2</sub>

<400> 8

Pro His Trp Ser Tyr Trp Leu Arg Pro

1 5

<210> 9

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (1) .. (1)

<223> 5-oxo-Pro

<220>

<221> MOD\_RES

<222> (6) .. (6)

<223> 2MeTrp

<220>

<221> MOD\_RES

<222> (9) .. (9)

<223> Pro-NH-CH<sub>2</sub>-CH<sub>3</sub>

<400> 9

Pro His Trp Ser Tyr Trp Leu Arg Pro

1 5

<210> 10

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (1) .. (1)

<223> 5-oxo-Pro

<220>

<223> C-term amidated

<400> 10

Pro His Trp Ser Tyr Gly Leu Arg Pro Gly

1 5 10

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (1) .. (1)

<223> 5-oxo-Pro

<220>

<221> MOD\_RES

<222> (6) .. (6)

<223> Ser(tBu)

<220>

<221> MOD\_RES

<222> (9) .. (9)

<223> Pro-NH-NH-CO-NH2

<400> 11

Pro His Trp Ser Tyr Ser Leu Arg Pro

1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (1) .. (1)

<223> 5-oxo-Pro

<220>

<221> MOD\_RES

<222> (6) .. (6)

<223> D3MeVal

<220>

<221> MOD\_RES

<222> (9)..(9)

<223> Pro-NH-C2H5

<400> 12

Pro His Trp Ser Tyr Val Leu Arg Pro

1 5